New therapeutic approaches such as stem cell and gene therapy are driving the need for clinical research on OA. Large amounts of X-ray data are produced in studies and need to be kept manageable. The combined efforts of ImageBiopsy Lab and IAG offer the tools to deal with this issue. ImageBiopsy Lab’s automated Kellgren & Lawrence scoring allows a standardized, objective and reproducible assessment on a large scale. With IAG paving the way for integrating this automated scoring system into clinical trials, this collaboration is reshaping the future of OA research.
CEO of IAG Dr. Olga Kubassova is as thrilled as the ImageBiopsy Lab team: “This is a great opportunity to aid our partners in clinical development in such a complex multi-faceted disease as osteoarthritis.”
About IAG
IAG has a strong presence in clinical trials and clinical decision making, and operates globally with offices in the EU and USA. The team, our academic and imaging partners are leading the integration of artificial intelligence and machine learning methodologies in all aspects of clinical trials: from data handling, data analysis to early go / no go decision making. Our property platform DYNAMIKA (ISO13485, CE, FDA510K) is used as a cloud based platform for integration of novel approaches related to quantitative imaging and allows to bring the latest thinking straight into clinical research programs. The platform is an integral part of CFR21 Part 11 compliant Quality Management System, which covers all aspects of clinical trial operations, data management, imaging site management and storage of imaging clinical data.
About Image Analysis Group (IAG)
Among others, IAG are globally involved in the design and conduct of studies. One the one hand, they offer consulting on trial design, both scientifically and financially, through their experienced advisory board. On the other hand, patented benchmarking libraries and an analytics platform offer the technical support needed for data analysis. IAG’s latest innovation is DYNAMIKA, a cloud-based data management platform which allows the integration of novel analysis tools into quantitative imaging. Being ISO13485, CE and FDA510K certified, the platform fulfills the high quality standards needed for clinical trials. Their trial solutions were applied on various modalities of medical imaging. The applications range from musculoskeletal diseases such as osteoarthritis to numerous types of cancers.
This collaboration is supported with €500,000 by Eurostars, a funding and support program by the European Union and EUREKA aimed to encourage R&D in niche markets.
Press contact
Richard Ljuhar
CEO and Managing Director
IB Lab GmbH – Image Biopsy Lab GmbH
Tel: +43 1 61067
E-Mail: r.ljuhar(at)imagebiopsy.com